Experimental and investigational drugs for the treatment of anal cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–1948.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Meadows HM, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017;18(3):347–356.
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–524.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–1921.
   PubMed Web of Science ®Google Scholar
• Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I). Br J Cancer. 2010;102(7):1123–1128.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–4351.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111(9):1726–1733.
   PubMed Web of Science ®Google Scholar
• Thind G, Johal B, Follwell M, et al. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol. 2014;9:124.
   PubMed Web of Science ®Google Scholar
• Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19:1094–1106.
   Web of Science ®Google Scholar
• Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446–453.
   PubMed Web of Science ®Google Scholar
• Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28(5):1036–1041.
   PubMed Web of Science ®Google Scholar
• Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015. Bethesda (MD): National Cancer Institute; 2018.
   Google Scholar
• Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17(3):354–356.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology - anal carcinoma. Version 2.2018. [Cited 2018 Oct 01]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/anal.pdf
   Google Scholar
• Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133–11142.
   PubMedGoogle Scholar
• Rao S, Scalafani F, Eng C, et al., editors. InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - an international rare cancers initiative (IRCI) trial. European Society for Medical Oncology (ESMO) 2018 Congress; Messe Munich, Germany. Proffered paper session - Gastrointestinal tumours, colorectal; 2018 Oct 24.
   Google Scholar
• Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(4):415–428.
   PubMed Web of Science ®Google Scholar
• Münger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63(10):4417–4421.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.
   PubMed Web of Science ®Google Scholar
• Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci USA. 1999;96(17):9557–9562.
   PubMed Web of Science ®Google Scholar
• Pagano M, Dürst M, Joswig S, et al. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene. 1992;7(9):1681–1686.
   PubMed Web of Science ®Google Scholar
• Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol. 1989;63(2):739–746.
   PubMed Web of Science ®Google Scholar
• Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–114.
   PubMed Web of Science ®Google Scholar
• Tommasino M, Adamczewski JP, Carlotti F, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene. 1993;8(1):195–202.
   PubMed Web of Science ®Google Scholar
• Darragh TM, Colgan TJ, Thomas Cox J, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. Int J Gynecol Pathol. 2013;32(1):76–115.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(4):314–319.
   PubMedGoogle Scholar
• Palefsky JM. Cutaneous and genital HPV-associated lesions in HIV-infected patients. Clin Dermatol. 1997;15(3):439–447.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(4):320–326.
   PubMedGoogle Scholar
• Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215–222.
   PubMed Web of Science ®Google Scholar
• Smola S. Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses. 2017;9(9):254.
   PubMed Web of Science ®Google Scholar
• Chung JH, Sanford E, Johnson A, et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol. 2016;27(7):1336–1341.
   PubMed Web of Science ®Google Scholar
• Siegel EM, Eschrich S, Winter K, et al. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014;57(8):941–957.
   PubMed Web of Science ®Google Scholar
• Morris V, Rao X, Pickering C, et al. Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal. Mol Cancer Res. 2017;15(11):1542–1550.
   PubMed Web of Science ®Google Scholar
• Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015;6(41):43594–43604.
   PubMedGoogle Scholar
• Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008;454(7205):776–779.
   PubMed Web of Science ®Google Scholar
• Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003;104(3):318–327.
   PubMed Web of Science ®Google Scholar
• Stelzer MK, Pitot HC, Liem A, et al. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res. 2010;3(12):1542–1551.
   PubMed Web of Science ®Google Scholar
• Sun ZJ, Zhang L, Zhang W, et al. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model. PLoS One. 2013;8(10):e74888.
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Scott AJ, Ma WW, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015;26(12):2505.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(4):496–508.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–S15.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15(7):413–448.
   PubMed Web of Science ®Google Scholar
• Paliga A, Onerheim R, Gologan A, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer. 2012;107(11):1864–1868.
   PubMed Web of Science ®Google Scholar
• Kim DW, Byer J, Kothari N, et al. EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology. 2017;92(4):190–196.
   PubMed Web of Science ®Google Scholar
• Rogers JE, Ohinata A, Silva NN, et al. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs. 2016;27(8):804–808.
   PubMed Web of Science ®Google Scholar
• Olivatto LO, Vieira FM, Pereira BV, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119(16):2973–2980.
   PubMed Web of Science ®Google Scholar
• Leon O, Guren MG, Radu C, et al. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740–2746.
   PubMed Web of Science ®Google Scholar
• Garg MK, Zhao F, Sparano JA, et al. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a Phase II eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205). J Clin Oncol. 2017;35(7):718–726.
   PubMed Web of Science ®Google Scholar
• Deutsch E, Lemanski C, Pignon JP, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013;24(11):2834–2838.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Palefsky J, et al. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a Phase II AIDS malignancy consortium trial. J Clin Oncol. 2017;35(7):727–733.
   PubMed Web of Science ®Google Scholar
• Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344–358.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178(5):3186–3197.
   PubMed Web of Science ®Google Scholar
• Pacini L, Ceraolo MG, Venuti A, et al. UV radiation activates toll-like receptor 9 expression in primary human keratinocytes, an event inhibited by human papillomavirus 38 E6 and E7 oncoproteins. J Virol. 2017;91(19):e01123-17.
   PubMed Web of Science ®Google Scholar
• Chang YE, Laimins LA. Interferon-inducible genes are major targets of human papillomavirus type 31: insights from microarray analysis. Dis Markers. 2001;17(3):139–142.
   PubMed Web of Science ®Google Scholar
• Oldak M, Tolzmann L, Wnorowski A, et al. Differential regulation of human papillomavirus type 8 by interferon regulatory factors 3 and 7. J Virol. 2011;85(1):178–188.
   PubMed Web of Science ®Google Scholar
• Schroer N, Pahne J, Walch B, et al. Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res. 2011;71(1):87–97.
   PubMed Web of Science ®Google Scholar
• Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011;187(3):1157–1165.
   PubMed Web of Science ®Google Scholar
• Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29(7):753–763.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086.
   Web of Science ®Google Scholar
• Welters MJ, de Jong A, van Den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63(3):636–641.
   PubMed Web of Science ®Google Scholar
• de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004;64(15):5449–5455.
   PubMed Web of Science ®Google Scholar
• Mouw KW, Cleary JM, Reardon B, et al. Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. Clin Cancer Res. 2017;23(12):3214–3222.
   PubMed Web of Science ®Google Scholar
• Perez K, Safran H, Leonard K, et al. A phase 1/2 evaluation of ADXS11-001 Lm-LLO immunotherapy, mitomycin, 5-fluorouracil (5-FU) and IMRT for anal cancer. Sex Health. 2015;12:76–92.
   PubMed Web of Science ®Google Scholar
• Eng C, Fakih M, Amin M, et al. P2 study of ADXS11-001 (AXAL) Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer. Ann Oncol. 2017;28(Suppl 5):181.
   Google Scholar
• Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178(1):361–366.
   PubMed Web of Science ®Google Scholar
• Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55(15):3369–3373.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25–ra25.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267–276.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–281.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol. 2011;8(10):577–585.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215–223.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Doran SL, Stevanovic S, et al. A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. J Clin Oncol. 2017;35:3009.
   Web of Science ®Google Scholar
• St Laurent J, Luckett R, Feldman S. HPV vaccination and the effects on rates of HPV-related cancers. Curr Probl Cancer. 2018; pii: S0147-0272(18):30135.
   Google Scholar
• National Cancer Institute. Cancer stat facts: anal cancer. Surveillance, epidemiology, and end results program (SEER) [Internet]. [cited 2018 Jan 10]. Available from: https://seer.cancer.gov/statfacts/html/anus.html
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Incidence, prevalence, and cost of sexually transmitted infections in the United States. CDC fact sheet [Internet]. [cited 2018 Jan 10]. Available from: https://www.cdc.gov/std/stats/STI-Estimates-Fact-Sheet-Feb-2013.pdf
   Google Scholar
• Centers for Disease Control and Prevention (CDC). More US adolescents up to date on HPV vaccination. CDC Newsroom [Internet]. [cited 2018 Jan 10]. Available from: https://www.cdc.gov/media/releases/2018/p0823-HPV-vaccination.html
   Google Scholar